Spastic paraplegia type 3A
Last updated 27 Apr 2021
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
Spastic paraplegia type 3A is one of a group of genetic disorders known as hereditary spastic paraplegias. These disorders are characterised by muscle stiffness (spasticity) and weakness in the lower limbs (paraplegia). Hereditary spastic paraplegias are often divided into two types: pure and complex. The pure types involve only the lower limbs, while the complex types also involve other areas of the body; additional features can include changes in vision, changes in intellectual functioning, difficulty walking, and disturbances in nerve function (neuropathy). Spastic paraplegia type 3A is usually a pure hereditary spastic paraplegia, although a few complex cases have been reported.
Video picks for Genetic conditionsVideo library
Description
Spastic paraplegia type 3A is one of a group of genetic disorders known as hereditary spastic paraplegias. These disorders are characterised by muscle stiffness (spasticity) and weakness in the lower limbs (paraplegia). Hereditary spastic paraplegias are often divided into two types: pure and complex. The pure types involve only the lower limbs, while the complex types also involve other areas of the body; additional features can include changes in vision, changes in intellectual functioning, difficulty walking, and disturbances in nerve function (neuropathy). Spastic paraplegia type 3A is usually a pure hereditary spastic paraplegia, although a few complex cases have been reported.
In addition to spasticity and weakness, which typically affect both legs equally, people with spastic paraplegia type 3A can also experience progressive muscle wasting (amyotrophy) in the lower limbs, reduced bladder control, an abnormal curvature of the spine (scoliosis), loss of sensation in the feet (peripheral neuropathy), or high arches of the feet (pes cavus). The signs and symptoms of spastic paraplegia type 3A usually appear before the age of 10; the average age of onset is 4 years. In some affected individuals the condition slowly worsens over time, sometimes leading to a need for walking support.
Inheritance patterns
The source lists the following possible inheritance patterns: Autosomal dominant. More than one pattern can apply in different cases.
Related genes
Other names
Spastic paraplegia 3
Spastic paraplegia 3A
SPG3A
Patient picks for Genetic conditions

Cancer
Brain tumours
This leaflet aims to give a brief overview of the various types of brain tumours. The treatment and survival rates vary greatly, depending on factors such as the type of tumour and the location in the brain.
by Dr Toni Hazell, FRCGP

Brain and nerves
Types of seizures
A seizure is a condition caused by a sudden burst of electrical activity in the brain. There are different types of seizures. This leaflet gives some information about what your doctor may wish to know and what tests may be advised after such an event.
by Dr Doug McKechnie, MRCGP

Diabetes
MHRA approves teplizumab to delay progression of type 1 diabetes
Teplizumab (Tzield) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to help delay the onset of Stage 3 type 1 diabetes (T1D). Read on to see what this means if you are prescribed teplizumab and what it does for you.
by Lawrence Higgins

Mental health
Types of eating disorders
In recent years, it's become clear that there are many people with different types of eating disorders who don't fit the classic profile of someone with anorexia or bulimia.
by Dr Hayley Willacy, FRCGP

Diabetes
Type 1 diabetes
Type 1 diabetes is the type of diabetes that typically develops in children and in young adults. In type 1 diabetes the body stops making insulin and the blood sugar (glucose) level goes very high. Treatment to control the blood glucose level is with insulin injections and a healthy diet. Other treatments aim to reduce the risk of complications. They include reducing blood pressure if it is high and advice to lead a healthy lifestyle.
by Dr Colin Tidy, MRCGP

Diabetes
Continuous glucose monitoring in type 1 diabetes
Type 1 and type 2 diabetes are both potentially serious conditions which should always be taken seriously. They’re both diagnosed on the basis of high blood sugar. But in other respects they are very, very different. Type 2 is largely down to lifestyle – getting type 1 is absolutely nothing to do with whether you eat too much sugar, carry excess weight or don’t exercise enough. People with type 2 diabetes often never need insulin – those with type 1 need it from day one. Many people with type 2 diabetes never need treatment that carries a risk of disabling low blood sugar (hypoglycaemia) – people with type 1 live with this risk every day. As a result, many people with type 2 never need to check their blood sugar several times a day – for people with type 1, it’s a highly unwelcome occupational hazard.
by Dr Sarah Jarvis
Related patient information and medicines

Patient information leaflet
Cerebral palsy
This may be before the baby is born, during the birth or soon after birth. What is cerebral palsy. Cerebral palsy is a name for a group of life-long conditions that have problems with muscle function and control. It is caused by brain injury or abnormal development of the brain that occurs while a child's brain is still developing. Types of.

Patient information leaflet
Nerve damage after epidural injection
A spinal injection Spinal anaesthetic is given directly into the fluid that surrounds your spinal cord (called the cerebrospinal fluid). The injection can be a local anaesthetic or a medicine to relieve pain. The risk of longer... Nerve damage to both legs (paraplegia) or death occurs between 1 in 54,500 to 1 in 141,500 spinal or epidural.

Patient information leaflet
Epidural pain relief after surgery
The content of this leaflet is used with the permission of the Royal College of Anaesthetists , the professional body responsible for the speciality throughout the UK, ensuring the quality of patient care through the maintenance of standards in anaesthesia, critical care and pain medicine. What is an epidural. An epidural is used for giving pain.

Patient information leaflet
Muscular dystrophy
Some genes control the proteins needed for muscle fibres to work properly. Genetic mutations can affect these genes, which are involved in MD. The 'faulty' gene in MD means that one of the proteins needed by muscle cells cannot be made correctly. The protein will either be lacking or will be a 'faulty' protein that does not work well. This leads.

Patient information leaflet
Paget's disease of bone
Paget's disease of bone affects the structure of parts of one or more bones. In most cases it causes no symptoms and does not need treatment. Symptoms develop in some cases and pain in the affected part of bone... What is Paget's disease of bone. Paget's disease of bone was first described by Sir James Paget in 1877. (It is a different condition.

Patient information leaflet
Ehlers-Danlos syndrome
It is not possible to generalise about the degree of learning difficulty that children experience as th... Musculocontractural Ehlers-Danlos syndrome Musculocontractural EDS (mcEDS) is a rare type of EDS in which muscles in the legs and arms are severely tightened and shortened - these are called muscle contractures. The skin is severely affected.
Further reading and references
- Spastic paraplegia type 3A; MedlinePlus, National Library of Medicine.
- Alvarez V, Sanchez-Ferrero E, Beetz C, Diaz M, Alonso B, Corao AI, Gamez J, Esteban J, Gonzalo JF, Pascual-Pascual SI, Lopez de Munain A, Moris G, Ribacoba R, Marquez C, Rosell J, Marin R, Garcia-Barcina MJ, Del Castillo E, Benito C, Coto E; Group for the Study of the Genetics of Spastic Paraplegia. Mutational spectrum of the SPG4 (SPAST) and SPG3A (ATL1) genes in Spanish patients with hereditary spastic paraplegia. BMC Neurol. 2010 Oct 8;10:89. doi: 10.1186/1471-2377-10-89.
- Blackstone C. Cellular pathways of hereditary spastic paraplegia. Annu Rev Neurosci. 2012;35:25-47. doi: 10.1146/annurev-neuro-062111-150400. Epub 2012 Apr 20.
- Ivanova N, Claeys KG, Deconinck T, Litvinenko I, Jordanova A, Auer-Grumbach M, Haberlova J, Lofgren A, Smeyers G, Nelis E, Mercelis R, Plecko B, Priller J, Zamecnik J, Ceulemans B, Erichsen AK, Bjorck E, Nicholson G, Sereda MW, Seeman P, Kremensky I, Mitev V, De Jonghe P. Hereditary spastic paraplegia 3A associated with axonal neuropathy. Arch Neurol. 2007 May;64(5):706-13. doi: 10.1001/archneur.64.5.706.
- Leonardi L, Marcotulli C, Santorelli FM, Tessa A, Casali C. De novo mutations in SPG3A: a challenge in differential diagnosis and genetic counselling. Neurol Sci. 2015 Jun;36(6):1063-4. doi: 10.1007/s10072-015-2097-1. Epub 2015 Jan 31. No abstract available.
- Leonardis L, Auer-Grumbach M, Papic L, Zidar J. The N355K atlastin 1 mutation is associated with hereditary sensory neuropathy and pyramidal tract features. Eur J Neurol. 2012 Jul;19(7):992-8. doi: 10.1111/j.1468-1331.2012.03665.x. Epub 2012 Feb 16.
- Namekawa M, Ribai P, Nelson I, Forlani S, Fellmann F, Goizet C, Depienne C, Stevanin G, Ruberg M, Durr A, Brice A. SPG3A is the most frequent cause of hereditary spastic paraplegia with onset before age 10 years. Neurology. 2006 Jan 10;66(1):112-4. doi: 10.1212/01.wnl.0000191390.20564.8e.
- Zhu PP, Soderblom C, Tao-Cheng JH, Stadler J, Blackstone C. SPG3A protein atlastin-1 is enriched in growth cones and promotes axon elongation during neuronal development. Hum Mol Genet. 2006 Apr 15;15(8):1343-53. doi: 10.1093/hmg/ddl054. Epub 2006 Mar 14.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

